- Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus)
- In the VAT08 Phase 3 primary series trial, two doses of the Sanofi-GSK vaccine in seronegative populations demonstrated:
- 100% efficacy against severe COVID-19 disease and hospitalizations
- 75% efficacy against moderate or severe COVID-19 disease
- 57.9% efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern
- Favorable safety profile following both primary series and booster vaccinations